文献速递免疫规划卫生政策与健康促进

评估荷兰老年人RSV疫苗接种策略的成本效益

Evaluating cost-effectiveness of RSV vaccination strategies for older adults in the Netherlands.
PubMed 文献 · Vaccine · 2025-09-25

本研究构建静态决策树成本效益模型,比较荷兰六个RSV流行季内不接种与多种老年人RSV疫苗接种策略。结果显示,每三年接种≥75岁及60-74岁高风险人群可预防约19000次全科就诊、3300例住院(含245例ICU入住)和870例死亡,成本效益比€30804/QALY;最具成本效益的策略为每三年接种≥75岁人群,ICER为23080/QALY。

要点

  • 每三年接种≥75岁人群相比不接种的ICER为23080/QALY,为最具成本效益策略。
  • 每三年接种所有≥60岁人群QALY增益最高,ACER为€39918/QALY,但相对≥75岁+高风险策略的ICER为€107623/QALY。

核心结论

  • 荷兰老年人RSV疫苗接种具有成本效益,尤其每三年接种一次时。

研究设计与样本

  • 静态决策树成本效益模型,比较不接种与多种RSV疫苗接种策略,覆盖荷兰成人六个RSV流行季,采用社会视角和终身时间 horizon。
  • 策略包括接种≥60岁、≥75岁、≥75岁联合60-74岁高风险人群,每种策略评估两年和三年间隔。
  • 疫苗有效性基于门诊环境的Meta分析 Efficacy 和住院环境的真实世界有效性数据;进行概率敏感性分析,支付意愿阈值为每QALY €50000。

主要发现

  • 每三年接种≥75岁及高风险组可在第一年预防约19000次全科就诊、3300例住院(含245例ICU入住)和870例死亡。
  • 每三年接种≥75岁人群相比不接种的ICER为23080/QALY。
  • 每三年接种所有≥60岁人群QALY增益最高,ACER为€39918/QALY;相比≥75岁+高风险策略的ICER为€107623/QALY,而≥75岁+高风险策略相比≥75岁单独策略的ICER为€61987/QALY。
  • 两年期策略ACER更高,在增量比较中处于劣势。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This study evaluates the cost-effectiveness of respiratory syncytial virus (RSV) vaccination for older adults in the Netherlands, aiming to identify the most effective vaccination strategy. METHODS: A static decision tree cost-effectiveness model was developed to compare no vaccination with various RSV vaccination strategies for Dutch adults over six RSV seasons. Strategies included vaccinating adults aged ≥60, ≥75, and ≥75 combined with high-risk individuals aged 60-74. Each was assessed with two- and three-year intervals. The model incorporated health outcomes and costs associated with RSV disease and vaccination from a societal perspective, with a lifetime horizon. Recent incidence data were used, and vaccine effectiveness was based on efficacy from a meta-analysis for outpatient settings and real-world effectiveness data for inpatient settings. A probabilistic sensitivity analysis was conducted, using a €50,000 per quality-adjusted life year (QALY) willingness-to-pay threshold. RESULTS: Vaccinating individuals aged ≥75 years and high-risk groups every three years could prevent approximately 19,000 general practitioner visits, 3300 hospitalizations (including 245 intensive care admissions), and 870 deaths in the first year. This strategy would avoid €29.5 million in healthcare costs and €6.3 million in productivity losses, gaining 2900 QALYs. It was cost-effective, with an average cost-effectiveness ratio (ACER) of €30,804/QALY. The most cost-effective strategy was vaccinating ≥75 year-olds every three years, with an incremental cost-effectiveness ratio (ICER) of 23,080/QALY compared to no vaccination. Vaccinating all ≥60-year-olds every three years resulted in the highest QALY gain, with an ACER of €39,918/QALY. Compared to the ≥75 and high-risk strategy, this approach had an ICER of €107,623/QALY, whereas the 75+ and high-risk strategy had an ICER of €61,987/QALY compared to the ≥75 strategy alone. Biennial strategies were associated with higher ACERs and were dominated in incremental comparisons. CONCLUSION: RSV vaccination for older adults in the Netherlands can be cost-effective, particularly when vaccinating every three years.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Zeevat F, Luttjeboer J, Korsten K, et al. Evaluating cost-effectiveness of RSV vaccination strategies for older adults in the Netherlands. Vaccine. 2025. PMID: 41015848. doi:10.1016/j.vaccine.2025.127735

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。